Clinical trial · no report yet · Phase 1
PAM
Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study
- NCT04262089 ↗
- Completed
- University Medical Center Groningen
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 2 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study
- Phase
- Phase 1
- Status
- Completed
- Conditions
- Uterine Cancer
- Interventions
- Pembrolizumab (Keytruda)
- Arms
- primary dMMR uterine cancer patients · Experimental
- primary POLE-EDM uterine cancer patients · Experimental
- Enrollment
- 10
- Primary outcomes
- The primary objective is to characterize pathologic responses (necrosis/viable tumor cells) in uterine cancer patients treated with neo-adjuvant pembrolizumab
- The primary objective is to characterize pathologic responses (Degree of immune infiltration) in uterine cancer patients treated with neo-adjuvant pembrolizumab
- The primary objective is to characterize pathologic responses (Degrees of inflammation, fibrosis, and mucin) in uterine cancer patients treated with neo-adjuvant pembrolizumab
- Sponsor
- University Medical Center Groningen with Merck Sharp & Dohme LLC
- Start
- Nov 1, 2020
- Primary completion
- Apr 17, 2023
- Results posted
- No
- Registry record
- NCT04262089 · updated Dec 5, 2023
Publications
linked from the registry- Eerkens AL, Brummel K, Vledder A, Paijens ST, Requesens M, Loiero D, van Rooij N, Plat A, Haan FJ, Klok P, Yigit R, Roelofsen T, de Lange NM, Klomp R, Church D, Ter Elst A, Wardenaar R, Spierings D, Foijer F, Koelzer VH, Bosse T, Bart J, Jalving M, Reyners AKL, de Bruyn M, Nijman HW. Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study. Nat Commun. 2024 Sep 3;15(1):7695. doi: 10.1038/s41467-024-52098-8. PubMed 39227583